SCHEDULE: Erik Otto Reports Stake in Chemomab Therapeutics

Erik Otto has filed a Schedule 13G, reporting beneficial ownership of 90,000 American Depository Shares in Chemomab Therapeutics Ltd., representing 1.2% of the class.

Summary

• Erik Otto has filed an amendment to Schedule 13G, indicating a change in beneficial ownership of Chemomab Therapeutics Ltd. (CMAB) American Depository Shares (ADS).
• The filing reports beneficial ownership of 90,000 ADSs.
• This ownership represents 1.2% of the class of securities outstanding as of May 14th, 2026.
• The reporting person certifies that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.

Positives

• Clear disclosure of beneficial ownership, enhancing transparency for investors.
• The reporting person certifies no intent to influence or control the issuer, suggesting a passive investment approach.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing does not offer insights into the company's operational performance or future prospects.

Risks

• The filing itself does not introduce new risks but is a disclosure of an existing ownership stake.
• Potential for future changes in ownership by this reporting person could impact share price dynamics.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual holders to report stakes exceeding 5% (or changes that bring them to or below that threshold). This filing indicates Erik Otto's position as a notable, albeit passive, shareholder in Chemomab Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes.
• Management: Awareness of a passive but notable shareholder position.

Next Steps

• Continued monitoring of Chemomab Therapeutics' filings for any further changes in beneficial ownership or strategic developments.

Key Dates

Keywords

Chemomab Therapeutics, Schedule 13G, Beneficial Ownership, American Depository Shares, Erik Otto, Ownership Stake